Digg icon reddit icon Stumbleupon icon
Print Email     Print Edition Stories

Monday, June 22, 2009

GTC receives second delisting notice

By Craig M. Douglas

Drug developer GTC Biotherapeutics Inc. has received its second delisting notice in three months from the Nasdaq Stock Market due to the company’s failure to maintain a minimum value threshold of $35 million for its publicly traded common stock.

The Framingham-based company has 90 days to regain compliance.

In March, GTC received a Nasdaq delisting notice for the same reason. Companies must maintain the $35 million minimum threshold for at least 10 consecutive trading days, per Nasdaq rules.

On May 26, GTC notified securities regulators of its intention to reduce its number of shares outstanding from roughly 104.4 million to 10.4 million.

The move was effective as of the market’s opening bell Wednesday, May 27. GTC’s stock (Nasdaq: GTCBD) opened Monday at $2.85 a share.

GTC (Nasdaq: GTCB) booked $16.7 million in revenue and a net loss of $22.7 million in 2008.

GTC develops therapeutic proteins produced through transgenic animal technology. Its ATryn antithrombin is approved for use in the United States and Europe.
 

Comments

If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.

Digg icon reddit icon Stumbleupon icon
Contact Editor Latest News

Tech Pulse Poll

What's your level of interest in Pinterest?



View Results

Stay Informed
Check which newsletter you'd like to receive.
TechFlash (Daily)
BioFlash (Daily)
GreenFlash (Weekly)
Startup Report (Weekly)
Breaking news, MHT events, local announcements
RSS feeds
Your email:

Affiliate publications: ACBJ.com, Boston Business Journal, Bizjournals.com, Portfolio.com, Wired.com

Web Site Developed by Neptune Web, Inc.

Use of and/or registration on any portion of this site constitutes acceptance of our User Agreement and Privacy Policy. About our ads.